Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026

trml

Selling, General and Administrative Expenses

Last Annual Value

22.75M

3-Year CAGR

3103%

5-Year CAGR

37%

10-Year CAGR

17%

Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Competitors Analysis of Selling, General and Administrative Expenses

TRML · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
22.75M
20.4%700.5%N/A 
62.89M
-30.6%10.1%N/A
34.33M
23.7%77.4%25.7%
33.80M
21.3%51.1%N/A
33.19M
9.0%8.6%N/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
70.13M
20.2%N/A-6.8%
56.71M
-8.9%-0.2%N/A
179.68M
39.0%48.1%29.7%
32.23M
-6.2%10.5%N/A
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Fair Value Envelope

TRML · NASDAQ

Our analysis suggests that TRML has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.98, this represents a potential HIDDEN relative to our calculated worth for Tourmaline Bio, Inc..

Intrinsic Value
Current Price: $47.98